Article
Allergy
Syed A. Shah, Holly Tibble, Rebecca Pillinger, Susannah McLean, Dermot Ryan, Hilary Critchley, David Price, Catherine M. Hawrylowicz, Colin R. Simpson, Ireneous N. Soyiri, Francis Appiagyei, Aziz Sheikh, Bright Nwaru
Summary: In a 17-year study, researchers found an association between hormonal replacement therapy (HRT) and a reduced risk of late onset asthma in menopausal women, with a dose-response relationship showing that longer duration of HRT use was linked to a greater reduction in asthma onset risk.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Review
Endocrinology & Metabolism
Shelli Graham, David F. Archer, James A. Simon, Kathleen M. Ohleth, Brian Bernick
Summary: This document reviewed and summarized the reported outcomes of menopausal hormone therapy (MHT) containing different estrogens and progesterone. The results suggested that MHT with estradiol (E2) and progesterone (P4) may have a potentially better safety profile compared to other estrogens and progestins, but further research is needed due to limitations of some studies.
GYNECOLOGICAL ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Chrisandra L. Shufelt, JoAnn E. Manson
Summary: Menopausal hormone therapy has varying effects on cardiometabolic markers and cardiovascular disease risk depending on formulation, dose, and route of delivery. Oral estrogens without progestogens have positive effects on lipoprotein levels, glycemia, insulin, and CVD risk, while adding progestogens blunts the lipid-related effects. Transdermal estrogens have less impact on coagulation, inflammation, and lipids compared to oral estrogens, potentially posing a lower risk of venous thromboembolism and stroke.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Multidisciplinary Sciences
Sung Eun Kim, Ji-Song Min, Saemi Lee, Dong-Yun Lee, DooSeok Choi
Summary: The effects of menopausal hormone therapy on non-alcoholic fatty liver disease were compared based on the route of estrogen administration. Transdermal estrogen was found to be beneficial in terms of NAFLD progression.
SCIENTIFIC REPORTS
(2023)
Article
Geriatrics & Gerontology
Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding
Summary: This study found that menopausal hormone therapy (MHT) with conjugated equine estrogen (CEE) was associated with an increased risk of hemorrhagic stroke (HS) in postmenopausal Taiwanese women. Women using CEE should discuss this risk with their clinicians in comparison to those using estradiol (E2) MHT.
Article
Geriatrics & Gerontology
Nick Panay, Rossella E. Nappi, Petra Stute, Santiago Palacios, Tomasz Paszkowski, Risa Kagan, David F. Archer, Julie Heroux, Mitra Boolell
Summary: This study compared the risk of venous thromboembolism between women treated with oral 17 beta-estradiol/micronized progesterone (E2/P4) and those treated with oral conjugated equine estrogens/medroxyprogesterone acetate (CEE/MPA). The study found that women receiving oral E2/P4 had a significantly lower risk of venous thromboembolism compared with those receiving oral CEE/MPA.
Article
Biochemistry & Molecular Biology
Parameswaran Grace Luther Lalitkumar, Eva Lundstrom, Birgitta Bystrom, Dorina Ujvari, Daniel Murkes, Edneia Tani, Gunnar Soderqvist
Summary: Recent studies have shown that estradiol (E-2)/natural progesterone (P) has a lower risk of breast cancer compared to conjugated equine estrogens (CEE)/synthetic progestogens. Differences in the regulation of breast cancer-related gene expression may provide an explanation for this.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Carolyn J. Crandall, Jaya M. Mehta, JoAnn E. Manson
Summary: Menopause usually occurs between 45 and 56 years of age due to loss of ovarian follicular activity. During this transition, a significant percentage of women experience vasomotor symptoms and genitourinary symptoms. Hormonal therapy with estrogen is effective in reducing the frequency of vasomotor symptoms, but it is not indicated for cardiovascular disease prevention.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Neurosciences
Muthuvel Jayachandran, Virginia M. Miller, Brian D. Lahr, Kent R. Bailey, Val J. Lowe, Julie A. Fields, Michelle M. Mielke, Kejal Kantarci
Summary: This study found an association between specific markers in blood microvesicles, summarized into two principal components, and brain amyloid-beta deposition in menopausal women. This suggests the feasibility of diagnosing and predicting Alzheimer's disease and related dementias at the population level.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Endocrinology & Metabolism
Beilei Bi, Yi Jiang, Yin Shi, Fan Ruan
Summary: The aim of this study was to evaluate the efficacy of bazedoxifene plus conjugated estrogens in treating menopausal symptoms in postmenopausal women. The results showed that treatment with BZA/CE significantly reduced the number of hot flushes, the percentage of parabasal cells, and the time to fall asleep compared to placebo. Sleep disturbance and total MENQOL also showed significant improvement. Additionally, BZA 20 mg/CE 0.625 mg was more effective than BZA 20 mg/CE 0.45 mg in improving menopausal symptoms.
GYNECOLOGICAL ENDOCRINOLOGY
(2022)
Article
Pathology
Mason C. Jager, Eunju Choi, Joy E. Tomlinson, Gerlinde van de Walle
Summary: This study examines the prevalence and severity of EqPV-H infections in diagnostic liver samples and finds that EqPV-H is associated with various histologic features in horses with clinical liver disease. The study also suggests that PCR assay may be unreliable for FFPE tissues. Therefore, EqPV-H should be considered as a differential diagnosis in cases of hepatitis other than Theiler's disease.
VETERINARY PATHOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Jarika Vatrasresth, Ammarin Suwan, Krasean Panyakhamlerd
Summary: Compared with a natural process, surgically induced menopausal women have a higher bone loss rate. Early treatment with estradiol valerate can significantly suppress the high bone remodeling in surgically induced menopausal women, indicating its potential benefits in preserving bone health in this population. Women who did not receive hormone treatment after surgery showed significantly elevated levels of bone turnover markers, highlighting the importance of early intervention in preventing bone loss in postmenopausal women.
Article
Pharmacology & Pharmacy
Meiyun Shi, Lei Yin, Yantong Sun, Can Wang, Lanlan Cai, Tinglan Zhang, Xiaotong Zhou, J. Paul Fawcett, Xiaoli Gao, Jingkai Gu
Summary: The pharmacokinetic behavior of conjugated equine estrogens in healthy Chinese postmenopausal women was investigated using a parallel two-column LC-MS/MS method. The results showed higher exposures of estrone and equilin in Chinese women compared to North American women.
CLINICAL PHARMACOKINETICS
(2022)
Article
Obstetrics & Gynecology
Micaela Sundell, Anna-Clara Spetz Holm, Mats Fredrikson, Mats Hammar, Mikael Hoffmann, Jan Brynhildsen
Summary: Oral menopausal hormone therapy increases the risk of pulmonary embolism, while transdermal administration does not. First ever users have the highest risk, but recurrent treatment is associated with lower risk.
Article
Gastroenterology & Hepatology
Muhammad Naeem, Marcello R. P. Markus, Mohammed Mousa, Sabine Schipf, Marcus Doerr, Antje Steveling, Ali Aghdassi, Jens-Peter Kuehn, Marie-Luise Kromrey, Matthias Nauck, Giovanni Targher, Henry Voelzke, Till Ittermann
Summary: The study found that larger liver volume assessed by MRI was associated with an increased risk of all-cause mortality, and this association was consistent in different subgroups. Higher serum liver enzyme levels and FIB-4 score were also significantly associated with higher risk of all-cause mortality.
LIVER INTERNATIONAL
(2022)
Letter
Hematology
Andrea Havasi, Gheorghe Doros, Vaishali Sanchorawala
AMERICAN JOURNAL OF HEMATOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Pooja Phull, Vaishali Sanchorawala, Lawreen H. Connors, Gheorghe Doros, Frederick L. Ruberg, John L. Berk, Shayna Sarosiek
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
(2018)
Article
Surgery
Brianna M. Krafcik, Alik Farber, Robert T. Eberhardt, Jeffrey A. Kalish, Denis Rybin, Gheorghe Doros, Steven L. Pike, Jeffrey J. Siracuse
ANNALS OF VASCULAR SURGERY
(2018)
Article
Cardiac & Cardiovascular Systems
Sammy Elmariah, Gheorghe Doros, Oscar R. Benavente, Deepak L. Bhatt, Stuart J. Connolly, Salim Yusuf, Steven R. Steinhubl, Yuyin Liu, Wen-Hua Hsieh, Robert W. Yeh, Laura Mauri
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2018)
Article
Cardiac & Cardiovascular Systems
Nasrien E. Ibrahim, Yang Song, Christopher P. Cannon, Gheorghe Doros, April Trebnick, Patricia Russo, Angelo Ponirakis, Claire Alexanian, James L. Januzzi
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2018)
Article
Cardiac & Cardiovascular Systems
James L. Januzzi, Annabel A. Chen-Tournoux, Robert H. Christenson, Gheorghe Doros, Judd E. Hollander, Phillip D. Levy, John T. Nagurney, Richard M. Nowak, Peter S. Pang, Darshita Patel, W. Franklin Peacock, E. Joy Rivers, Elizabeth L. Walters, Hanna K. Gaggin
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Article
Urology & Nephrology
Karim Sultan Haider, Ahmad Haider, Gheorghe Doros, Abdulmaged Traish
JOURNAL OF UROLOGY
(2018)
Article
Surgery
Mohammad H. Eslami, Denis V. Rybin, Gheorghe Doros, Jeffrey J. Siracuse, Alik Farber
JOURNAL OF VASCULAR SURGERY
(2018)
Article
Surgery
Brianna M. Krafcik, Thomas W. Cheng, Alik Farber, Jeffrey A. Kalish, Denis Rybin, Gheorghe Doros, Jeffrey J. Siracuse
JOURNAL OF VASCULAR SURGERY
(2018)
Article
Hematology
Brian Lilleness, Frederick L. Ruberg, Roberta Mussinelli, Gheorghe Doros, Vaishali Sanchorawala
Letter
Hematology
Vaishali Sanchorawala, Gheorghe Doros, Anthony C. Shelton
AMERICAN JOURNAL OF HEMATOLOGY
(2019)
Letter
Oncology
Jose Acevedo, Gheorghe Doros, Raphael Szalat, Vaishali Sanchorawala
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Oncology
Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H. Connors, Lisa M. Mendelson, Tracy Joshi, Vaishali Sanchorawala
Summary: In recent decades, there have been significant advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis, leading to improved outcomes and decreased early mortality. However, wide survival gaps still exist among different patient subgroups, with most deaths attributed to disease-related factors such as cardiac failure and sudden unexpected death. AL amyloidosis-unrelated mortality has increased over time and with longer-term survival, highlighting the changing landscape of care standards and the overall optimistic outlook for patients with AL amyloidosis.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Andrew Staron, Lawreen H. Connors, Luke Zheng, Gheorghe Doros, Vaishali Sanchorawala
BLOOD CANCER JOURNAL
(2020)
Article
Cardiac & Cardiovascular Systems
Nasrien E. Ibrahim, Hanna K. Gaggin, Alexander Turchin, Harshali K. Patel, Yang Song, April Trebnick, Gheorghe Doros, Juan F. Maya, Christopher P. Cannon, James L. Januzzi
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2019)